Enrollment completed in Ph 2/3 COMPANION-002 trial of CTX-009 + paclitaxel in patients with 2L advanced Metastatic or Recurrent Biliary Tract Cancers (BTC) August 13, 2024
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical August 13, 2024
Ph 3 KeyVibe-008 Trial of Vibostolimab + Pembrolizumab in Patients With Extensive-Stage SCLC to be discontinued as per IDMC recommendations August 13, 2024
Sarclisa induction treatment demonstrated significantly improved PFS in patients with newly diagnosed multiple myeloma eligible for transplant August 13, 2024
FDA Clears IND Application for Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) August 13, 2024
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers August 13, 2024
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines August 13, 2024
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai to Discover and Develop Novel Molecular Glue Degraders for Oncology Indications August 13, 2024
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 August 13, 2024
FAILED TRIAL: FOCUS Ph II Trial of UV1 + Pembrolizumab didn’t improve PFS & OS in Patients with Metastatic or Recurrent Head and Neck Cancer August 13, 2024
Initial Data from Ph 1 Clinical Trial of EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 announced August 13, 2024
FDA provides IND requirements for the development of ALA-101 in first-inhuman clinical trials for lymphoma and leukaemia August 13, 2024
FDA accepts Supplemental NDA for Cabozantinib for Patients with Advanced Neuroendocrine Tumors August 13, 2024
FDA grants “Study May Proceed” letter for the Ph 1/2 study of Silmitasertib (CX-4945) + chemo in children and young adults with R/R solid tumors August 13, 2024
Supplemental NDA of Opdivo – Yervoy Combo submitted in Japan to Expand the Use for Unresectable HCC August 13, 2024
FDA Approves LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with R/R Cutaneous T-Cell Lymphoma August 13, 2024
